These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. ARNi: A Novel Approach to Counteract Cardiovascular Diseases. Volpe M; Rubattu S; Battistoni A Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035359 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. Volpe M; Tocci G; Battistoni A; Rubattu S High Blood Press Cardiovasc Prev; 2015 Sep; 22(3):241-6. PubMed ID: 26100410 [TBL] [Abstract][Full Text] [Related]
4. Current role of neprilysin inhibitors in hypertension and heart failure. von Lueder TG; Atar D; Krum H Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition. Volterrani M; Iellamo F; Senni M; Piepoli MF Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730 [TBL] [Abstract][Full Text] [Related]
8. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Díez J Eur J Heart Fail; 2017 Feb; 19(2):167-176. PubMed ID: 27766748 [TBL] [Abstract][Full Text] [Related]
9. [Neprilysin inhibition and chronic kidney disease]. Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831 [TBL] [Abstract][Full Text] [Related]
10. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. Liu RC Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980 [TBL] [Abstract][Full Text] [Related]
11. Neurohumoral Activation in Heart Failure. Manolis AA; Manolis TA; Manolis AS Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895150 [TBL] [Abstract][Full Text] [Related]
12. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. D'Elia E; Iacovoni A; Vaduganathan M; Lorini FL; Perlini S; Senni M Eur J Heart Fail; 2017 Jun; 19(6):710-717. PubMed ID: 28326642 [TBL] [Abstract][Full Text] [Related]
13. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. Braunwald E J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951 [TBL] [Abstract][Full Text] [Related]
14. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. Vardeny O; Miller R; Solomon SD JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. Docherty KF; McMurray JJV Int J Cardiol; 2019 Apr; 281():179-185. PubMed ID: 29891240 [TBL] [Abstract][Full Text] [Related]
16. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation. Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis. Vasquez N; Carter S; Grodin JL Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. Chrysant SG J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. Gori M; Volterrani M; Piepoli M; Senni M Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659 [TBL] [Abstract][Full Text] [Related]